Medications for Herpes Zoster Treatment
For uncomplicated herpes zoster in immunocompetent adults, initiate oral valacyclovir 1 gram three times daily for 7–10 days, continuing until all lesions have completely scabbed. 1, 2
First-Line Oral Antiviral Regimens
Standard Dosing Options
Valacyclovir 1000 mg orally three times daily for 7–10 days is the preferred first-line agent due to superior bioavailability and convenient dosing compared to acyclovir 1, 2, 3
Famciclovir 500 mg orally three times daily for 7–10 days offers equivalent efficacy to valacyclovir with similar dosing convenience 1, 4
Acyclovir 800 mg orally five times daily for 7–10 days remains effective but requires more frequent dosing, which may reduce adherence 1, 2, 5
Critical Timing Considerations
Treatment must be initiated within 72 hours of rash onset for optimal efficacy in reducing acute pain, accelerating lesion healing, and preventing postherpetic neuralgia 1, 6
Peak viral shedding occurs in the first 24 hours after lesion onset, making early intervention essential 1
The therapeutic endpoint is complete crusting of all lesions, not an arbitrary 7-day duration—continue treatment until this clinical milestone is reached 1, 2
Intravenous Therapy Indications
When to Escalate to IV Acyclovir
Switch to intravenous acyclovir 10 mg/kg every 8 hours when any of the following are present: 1, 2
- Disseminated herpes zoster (≥3 dermatomes, visceral involvement, or hemorrhagic lesions)
- Severe immunosuppression (active chemotherapy, HIV with low CD4 count, organ transplantation)
- Central nervous system complications (encephalitis, meningitis, Guillain-Barré syndrome)
- Complicated facial or ophthalmic disease with risk of cranial nerve involvement
- Lack of clinical improvement after 7–10 days of appropriate oral therapy (suspect acyclovir resistance)
IV Therapy Duration and Monitoring
Continue IV acyclovir for a minimum of 7–10 days and until clinical resolution is attained (all lesions crusted, fever resolved) 1, 2
Monitor renal function at initiation and once or twice weekly during IV therapy; adjust dosing for any renal impairment 1
Assess for thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in immunocompromised patients receiving high-dose therapy 1
Switch to oral therapy once clinical improvement occurs to complete the treatment course 2
Dose Adjustments for Renal Impairment
Valacyclovir Renal Dosing
Measure serum creatinine and calculate creatinine clearance before initiating therapy to stratify nephrotoxicity risk and guide dose modification: 1
| Creatinine Clearance | Valacyclovir Dose |
|---|---|
| 30–49 mL/min | 1000 mg every 12 hours |
| 10–29 mL/min | 1000 mg every 24 hours |
| <10 mL/min | 500 mg every 24 hours |
Famciclovir Renal Dosing
Famciclovir requires dose adjustment to prevent acute renal failure: 1
| Creatinine Clearance | Famciclovir Dose |
|---|---|
| ≥60 mL/min | 500 mg every 8 hours |
| 40–59 mL/min | 500 mg every 12 hours |
| 20–39 mL/min | 500 mg every 24 hours |
| <20 mL/min | 250 mg every 24 hours |
Hydration and Monitoring
- Ensure adequate hydration during systemic antiviral therapy to reduce the risk of crystalluria and acyclovir-induced nephropathy, which occurs in up to 20% of patients 1
Management in Immunocompromised Patients
Antiviral Therapy Modifications
For severely immunocompromised patients with uncomplicated herpes zoster, use higher oral doses: acyclovir 400 mg orally 3–5 times daily until clinical resolution 1
Intravenous acyclovir 10 mg/kg every 8 hours is mandatory for immunocompromised patients with disseminated disease, multi-dermatomal involvement, or visceral complications 1, 2
Immunocompromised patients may require extended treatment duration beyond 7–10 days because lesions develop over longer periods (7–14 days) and heal more slowly 1
Immunosuppressive Medication Management
Consider temporary reduction or discontinuation of immunosuppressive medications in cases of disseminated or invasive herpes zoster if clinically feasible 1, 2
Re-introduce immunosuppressive agents only after all vesicular lesions have crusted, fever has resolved, and the patient has shown clinical improvement on antiviral therapy 1
Treatment of Acyclovir-Resistant Herpes Zoster
Recognition of Treatment Failure
Suspect acyclovir resistance when cutaneous lesions have not begun to resolve within 7–10 days after starting appropriate therapy 1
Confirmed acyclovir-resistant VZV is rare in immunocompetent adults but occurs in up to 7% of immunocompromised patients 1
Obtain viral culture with susceptibility testing to confirm resistance 1
Alternative Therapy
For laboratory-confirmed acyclovir-resistant VZV, switch to foscarnet 40 mg/kg intravenously every 8 hours until clinical resolution of lesions 1, 2
All acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir 1
Foscarnet requires close monitoring of renal function and electrolytes (hypocalcemia, hypophosphatemia, hypomagnesemia, hypokalemia) 2
Analgesic Medications for Acute Zoster Pain
First-Line Neuropathic Pain Management
Gabapentin is the first-line oral agent for acute neuropathic pain due to herpes zoster, titrated in divided doses up to 2400 mg per day 1
Gabapentin improves sleep quality but causes somnolence in approximately 80% of treated individuals—counsel patients about this common adverse effect 1
Pregabalin may be added for patients whose pain remains uncontrolled with gabapentin alone, particularly in postherpetic neuralgia 1
Adjunctive Systemic Therapies
Serotonin-norepinephrine reuptake inhibitors (SNRIs) can be considered as adjuncts, drawing on their demonstrated efficacy in broader neuropathic pain populations 1
Tricyclic antidepressants, antiseizure drugs, and opioids all offer some pain relief and may be combined 6
Topical Analgesics
A single application of an 8% capsaicin patch (or a 30-minute cream application) provides analgesia lasting at least 12 weeks for chronic peripheral neuropathic pain 1
To mitigate the erythema and burning associated with capsaicin, apply a 4% lidocaine preparation for 60 minutes, then remove before capsaicin administration 1
Over-the-counter analgesics such as acetaminophen and ibuprofen are recommended to relieve acute pain in otherwise healthy adults 1
Topical anesthetics provide minimal benefit and are not recommended as primary therapy for acute zoster pain management 1
Corticosteroid Use: Contraindications and Limited Role
When to Avoid Corticosteroids
Prednisone should generally be avoided in immunocompromised patients with shingles due to increased risk of disseminated infection 1
Patients with poorly controlled diabetes, history of steroid-induced psychosis, severe osteoporosis, or prior severe steroid toxicity should avoid prednisone 1
Topical corticosteroid cream applied to active shingles rash can increase the risk of severe disease and dissemination, particularly in immunocompromised patients 1
Limited Adjunctive Role
- Prednisone may be used as adjunctive therapy to antivirals in select cases of severe, widespread shingles flares, but carries significant risks (infections, hypertension, myopathy, glaucoma, aseptic necrosis, cataracts, Cushing syndrome, weight gain, osteopenia) that do not outweigh benefits in most patients 1
Post-Exposure Prophylaxis
Varicella-Zoster Immune Globulin (VZIG)
For varicella-susceptible patients exposed to active varicella zoster infection, administer VZIG within 96 hours of exposure 1, 2
VZIG is recommended for high-risk populations including pregnant women, immunocompromised patients, and premature newborns <28 weeks gestation or <1,000 g 1
Alternative Prophylaxis
- If VZIG is unavailable or more than 96 hours have passed, initiate a 7-day course of oral acyclovir beginning 7–10 days after varicella exposure 1, 2
Vaccination for Prevention
Recombinant Zoster Vaccine (Shingrix)
The recombinant zoster vaccine (Shingrix) is strongly recommended for all adults aged ≥50 years, regardless of prior herpes zoster episodes, providing >90% efficacy in preventing future episodes 1, 2
Vaccination should ideally occur before initiating immunosuppressive therapies when possible, but can also be given after recovery from an acute episode 1
For patients already receiving B-cell depleting therapy, administer Shingrix at least 4 weeks prior to the next scheduled dose to maximize immunogenicity 1
Common Pitfalls to Avoid
Do not discontinue antiviral therapy at exactly 7 days if lesions have not fully crusted—short-course therapy designed for genital herpes is inadequate for VZV infection 1
Do not rely on topical antiviral therapy, which is substantially less effective than systemic therapy and is not recommended 1, 2
Do not delay escalation to IV acyclovir in immunocompromised patients or those with severe disease 1
Do not start treatment too late—efficacy decreases significantly when treatment is initiated after 72 hours from rash onset 6